title: The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis.
abstract: We report our single institution's effort to standardize the method of collecting peripheral blood progenitor cells (PBPC) used for autologous transplantation. PBPC were mobilized by different types of chemotherapy followed by G-CSF (24 patients) or G-CSF alone (six patients) in 30 patients with various underlying neoplastic diseases. A median of three aphereses (range: 2-7), using the CS3000 cell separator was performed and a blood volume of 101 was processed. We studied the relationship between the absolute numbers of circulating leukocytes, mononuclear cells and CD34+ cells and the amount of PBPC collected during a single apheresis procedure. CD34+ cells were quantified by leukocyte subset analysis based on flow cytometry. Both CFU-GM and CD34+ cell contents of the apheresis products (69 procedures analyzed) correlated strongly: rho = 0.936, P = 0.0001). Regression analysis showed that the total number of CD34+ cells or CFU-GM content of the apheresis products could be predicted (r = 0.915, P = 0.0001) from the absolute number of CD34+ cells in the blood. A number of 10 circulating CD34+ cells per mm3 blood ensured a minimum of 0.5 x 10(6) CD34+ cells per kg, collected on the same day. Of the 30 patients, 17 received an autologous graft that contained only PBPC in 13. Long-term and complete hematological reconstitution was observed in all patients who had a minimum of 2 x 10(6) CD34+ cells per kg reinfused.
authors.affiliation: Division of Hematology and Immunology, Brussels, Belgium.
authors.forename: R
authors.initials: R
authors.lastname: Schots
authors.forename: I
authors.initials: I
authors.lastname: Van Riet
authors.forename: S
authors.initials: S
authors.lastname: Damiaens
authors.forename: J
authors.initials: J
authors.lastname: Flament
authors.forename: P
authors.initials: P
authors.lastname: Lacor
authors.forename: Y
authors.initials: Y
authors.lastname: Staelens
authors.forename: L
authors.initials: L
authors.lastname: Steenssens
authors.forename: B
authors.initials: B
authors.lastname: van Camp
authors.forename: M
authors.initials: M
authors.lastname: De Waele
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D001772:Blood Cell Count; D001781:Blood Component Removal / Q000379:methods* / Q000706:statistics & numerical data; D001853:Bone Marrow / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000494:pharmacology; D005260:Female; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D008297:Male; D008558:Melphalan / Q000494:pharmacology; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000628:therapy; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods
chemical_list: D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D008558:Melphalan